Alzheimer's disease (AD) represents the most common cause of dementia worldwide and has been consistently associated with the loss of basal forebrain cholinergic neurons (BFCNs) leading to impaired cholinergic neurotransmission, aberrant synaptic function, and altered structural lipid metabolism. In this sense, membrane phospholipids (PLs) can be used for de novo synthesis of choline (Ch) for the further obtaining of acetylcholine (ACh) when its availability is compromised. Specific lipid species involved in the metabolism of Ch have been identified as possible biomarkers of phenoconversion to AD. Using a rat model of BFCN lesion, we have evaluated the lipid composition and muscarinic signaling in brain areas related to cognitive processes. The loss of BFCN resulted in alterations of varied lipid species related to Ch metabolism at nucleus basalis magnocellularis (NMB) and cortical projection areas. The activity of muscarinic receptors (mAChR) was decreased in the NMB and increased in the hippocampus according to the subcellular distribution of M1/M2 mAChR which could explain the learning and memory impairment reported in this AD rat model. These results suggest that the modulation of specific lipid metabolic routes could represent an alternative therapeutic strategy to potentiate cholinergic neurotransmission and preserve cell membrane integrity in AD.
Alzheimer's disease (AD) represents the most common cause of dementia worldwide and has been consistently associated with the loss of basal forebrain cholinergic neurons (BFCNs) leading to impaired cholinergic neurotransmission, aberrant synaptic function, and altered structural lipid metabolism. In this sense, membrane phospholipids (PLs) can be used for de novo synthesis of choline (Ch) for the further obtaining of acetylcholine (ACh) when its availability is compromised. Specific lipid species involved in the metabolism of Ch have been identified as possible biomarkers of phenoconversion to AD. Using a rat model of BFCN lesion, we have evaluated the lipid composition and muscarinic signaling in brain areas related to cognitive processes. The loss of BFCN resulted in alterations of varied lipid species related to Ch metabolism at nucleus basalis magnocellularis (NMB) and cortical projection areas. The activity of muscarinic receptors (mAChR) was decreased in the NMB and increased in the hippocampus according to the subcellular distribution of M1/M2 mAChR which could explain the learning and memory impairment reported in this AD rat model. These results suggest that the modulation of specific lipid metabolic routes could represent an alternative therapeutic strategy to potentiate cholinergic neurotransmission and preserve cell membrane integrity in AD.
Alzheimer’s
disease (AD) is the most frequent irreversible
form of dementia, characterized by a progressive cognitive impairment.
The specific vulnerability of the cholinergic system at the basalocortical
pathway has been extensively described in AD. This decline includes
the loss of basal forebrain cholinergic neurons (BFCNs), decrease
in choline acetyltransferase (ChAT) activity and density of the high-affinity
choline uptake carrier, and altered density of muscarinic receptors
(mAChR), leading to severe cholinergic neurotransmission deficiencies.[1−5] Changes in cholinergic neurotransmission were identified as responsible
for the short-term learning deficits and memory loss described at
the onset of adult dementia disorders.[6] Moreover, the activity of muscarinic antagonists inducing amnesia
and cognitive impairment was also described decades ago.[7] Altogether, they contributed to formulate the
cholinergic hypothesis of geriatric memory dysfunction at that time.[8] The biosynthesis of acetylcholine (ACh) critically
depends on the levels of choline (Ch).[9] Ch can be obtained mainly from the hydrolysis of ACh, presynaptic
uptake, and circulating Ch in the bloodstream and derived from the
hydrolysis of membrane phospholipids at the expense of membrane formation
when other sources are compromised.[10] This
metabolic source may finally impair synaptic plasticity or compromise
membrane viability leading to autophagy mechanisms as an adaptive
response to stress provoked by the cholinergic dysfunction described
in the neurodegenerative process of AD.[11−14]The loss of BFCNs leads
to a decrease in the production and release
of ACh in both the basal cholinergic forebrain and in innervated cortical
areas, with the consequent reduction in the pool of Ch available for
ACh synthesis. The BFCNs from the nucleus basalis magnocellularis
(NBM) innervate most of the cerebral cortex, provide the main source
of cortical ACh, and control learning and memory processes. In this
regard, 192IgG-saporin (SAP), an immunotoxin directed against the
low affinity nerve growth factor receptor p75NTR, mainly expressed
in BFCN, represents a powerful tool to specifically eliminate those
cells to mimic the cholinergic degeneration described in AD.[15] The intraparenchymal infusion of 192IgG-saporin
in the NBM of rats decreases ChAT and acetylcholinesterase (AChE)
levels, reduces the density of the high-affinity Ch transporter, and
modifies the activity and cellular distribution of mAChR (see review
from ref (16)). Consequently,
the loss of BFCN impairs learning and memory.[17] Intraparenchymal injection of SAP in the NBM results in deficits
in recognition memory capacity, in delayed matching to position, association
learning, and aversive learning and memory. Attentional functions
are also impaired including vigilance, reorienting of spatial attention,
and attentional resources directed at environmental stimuli.[18,19] Previous results clearly demonstrated that the protocol used in
the present study is able to induce deficits in aversive learning,[17] spatial memory by using the Barnes maze as a
nonaversive spatial navigation test,[20] or
learning and memory related to novelty-seeking by novel object recognition
test (unpublished results).Lipids (mainly phospholipids; PL),
which are the main structural
components of membranes, are also involved in the control of multiple
signaling pathways and energy metabolism. Different studies have described
changes in the abundance and distribution of several of these lipid
species in AD.[21−27] Several attempts to alleviate the deficit of ACh in AD patients
by the administration of cholinergic enhancers or precursors such
as Ch or lecithin have failed, while those based on phosphatidylserine,
Ch-alphoscerate, and CDP-Ch displayed slight benefits (reviewed in
ref (28)). Despite
the limited therapeutic effects of cholinergic enhancers, the AChE
inhibitors together with memantine continue being the only approved
drugs available for AD treatment.[29] These
treatments are not able to reverse the progressive cholinergic neurodegeneration
as the primary cause is not treated since it has not been identified.
However, the direct modulation of phospholipids involved in neurotransmission
signaling may represent an alternative therapeutic strategy to potentiate
cholinergic neurotransmission in AD. Currently, it is possible to
anatomically localize the diversity and specialization of lipid content
in discrete brain areas of humans as well as in rodents by using matrix-assisted
laser desorption ionization-imaging mass spectrometry (MALDI-IMS).[27,30] The combination of this technique with neurochemical and behavioral
studies is already contributing to the understanding of the physiological
role of specific lipid species in the underlying pathological mechanisms
involved in cognitive impairment.[31]Thus, the present study analyzes by MALDI-IMS the modulation mediated
by mAChR signaling of specific PL in the basalocortical pathway following
the specific depletion of BFCN to identify a possible alternative
restoration of cholinergic neurotransmission during AD progression.
Results
and Discussion
Learning and Memory Impairment after Basal
Forebrain Cholinergic
Lesion
One week after the administration of the immunotoxin
192IgG-saporin, cognitive functions related to learning and memory
processes were evaluated in the passive avoidance test (PA) (Figure A). The results of
a study carried out in a separate group of animals are shown to validate
the usefulness of the PA test in this rat model of AD, since recent
studies demonstrated that the modulation of cholinergic neurotransmission
modifies the perception of pain when using nociceptive stimuli-based
learning tests.[32] Comparable electric-shock-evoked
first vocalizations (pain threshold) between vehicle (artificial cerebrospinal
fluid; aCSF) and lesioned (SAP) treated groups (p = ns vs aCSF) were observed when electric shocks of increasing intensity
were delivered (Figure B), which demonstrates for the first time that cholinergic neurotransmission
arising from NBM does not substantially contribute to bias the perception
of pain in the PA test.
Figure 1
(A) Acquisition latency times in the learning
trial of the passive
avoidance test of SHAM (n = 6), aCSF (n = 36), and SAP (n = 36) rats. (B) Electrical intensity
(mA) required to provoke the first audible vocalization when delivering
increasing intensities of foot-shock to aCSF (n =
8) and SAP (n = 11) rats (p = ns
aCSF vs SAP). (C) Step-through latency times in the retention trial,
represented as Kaplan–Meier survival curves. The median step-through
latency or the time spent to enter the dark compartment by 50% of
the immunotoxin-treated rats was calculated in 102.9 s (aCSF vs SHAM, p = ns; SAP vs aCSF p < 0.001, log-rank
test). (D, E) AChE staining in brain sections at three different levels
of aCSF and SAP-treated rats. (F) Microphotographs from somatosensory
cortex of aCSF and SAP-treated rats at 400-fold magnification, revealing
decreased AChE positive fibers in the immunotoxin-treated rats (scale
bar = 20 μm). (G) Optical density of AChE expressed as percentages
of the striatal levels (used as control area) in aCSF (n = 13) and SAP (n = 13) treated rats: *p < 0.05, **p < 0.01, and ***p < 0.001 SAP vs aCSF-treated rats. Outliers are indicated by black
dots or circles in the G panel. MS: medial septum. Cg: cingulate cortex.
Mot: motor cortex. Ss: somatosensory cortex. Pir: piriform cortex.
Ent: entorhinal cortex. Amyg: amygdaloid nuclei (Bla, basolateral;
Ant, anterior; Lat, lateral; Cent, central; Med, medial). DG: dentate
gyrus. CA1-CA2-CA3: hippocampal CA1-CA2-CA3 regions. Str: striatum.
(A) Acquisition latency times in the learning
trial of the passive
avoidance test of SHAM (n = 6), aCSF (n = 36), and SAP (n = 36) rats. (B) Electrical intensity
(mA) required to provoke the first audible vocalization when delivering
increasing intensities of foot-shock to aCSF (n =
8) and SAP (n = 11) rats (p = ns
aCSF vs SAP). (C) Step-through latency times in the retention trial,
represented as Kaplan–Meier survival curves. The median step-through
latency or the time spent to enter the dark compartment by 50% of
the immunotoxin-treated rats was calculated in 102.9 s (aCSF vs SHAM, p = ns; SAP vs aCSF p < 0.001, log-rank
test). (D, E) AChE staining in brain sections at three different levels
of aCSF and SAP-treated rats. (F) Microphotographs from somatosensory
cortex of aCSF and SAP-treated rats at 400-fold magnification, revealing
decreased AChE positive fibers in the immunotoxin-treated rats (scale
bar = 20 μm). (G) Optical density of AChE expressed as percentages
of the striatal levels (used as control area) in aCSF (n = 13) and SAP (n = 13) treated rats: *p < 0.05, **p < 0.01, and ***p < 0.001 SAP vs aCSF-treated rats. Outliers are indicated by black
dots or circles in the G panel. MS: medial septum. Cg: cingulate cortex.
Mot: motor cortex. Ss: somatosensory cortex. Pir: piriform cortex.
Ent: entorhinal cortex. Amyg: amygdaloid nuclei (Bla, basolateral;
Ant, anterior; Lat, lateral; Cent, central; Med, medial). DG: dentate
gyrus. CA1-CA2-CA3: hippocampal CA1-CA2-CA3 regions. Str: striatum.Then, the animals used for the neurochemical studies
were tested
in the PA. The phase of acquisition or learning revealed no differences
between aCSF and SAP groups (Figure A). Twenty-four hours later, rats were again tested
to evaluate memory and retrieval of the aversive stimulus by measuring
the step-through latency. On the basis of previous reports, Kaplan–Meier
survival curves were used to determine and graphically represent the
probability of a positive response (i.e., reaching the cutoff time
of 300 s).[17,33] When the three groups were compared,
100% and 78% of control (SHAM) and aCSF-treated rats, respectively
(p = ns), remembered the aversive stimulus, while only 40% of immunotoxin-treated
rats displayed a positive response (p = 0.0001 vs
SHAM and p = 0.0006 vs aCSF) which showed a median
latency time of 102.9 s for SAP-treated rats (Figure C). The negative behavioral responses in
the PA test following the depletion of approximately 80% of BFCN are
consistent with the observations of other authors.[30,34,35]AChE enzymatic assay was used to verify
the status of the cholinergic
lesion induced by the 192IgG-saporin. SHAM-operated rats showed equivalent
levels of AChE staining to those measured in the aCSF-treated group
(data not shown). SAP did not modify the AChE+ fiber density in the
striatum but resulted in an extensive reduction in the entire cortical
mantle, ranging from 20% in cingular (p < 0.01)
and piriform (p < 0.05) to 60–70% in motor
and entorhinal cortices (p < 0.001), indicating
the specificity of the lesion to BFCN of the NBM. No differences were
observed in the medial septum or hippocampus, revealing additional
evidence of the absence of nonspecific damage in other basal forebrain
cholinergic projection pathways (Figure D,G). A previous study showed that the loss
of 50% of BFCN in the NBM leads to a 25–30% decrease in ChAT
activity[36] which is consistent with the
present data.
Modulation of the Lipid Profile in NBM and
Cortex Induced by
BFCN Lesion
The MALDI-IMS technique allowed us to anatomically
localize and quantify several lipid species in tissue sections. In
this study, a lipidomic analysis was carried out in coronal brain
sections including the NBM and several cortical regions, from aCSF
or SAP groups in both positive and negative ion detection modes. The
PL composition of potential Ch precursors was specifically analyzed
in the lesion site and cortical projections.First, MALDI-IMS
was performed in positive ion detection mode, and more than 300 peaks
were obtained. There were changes in the relative levels of several
phosphatidylcholine (PC) species in the NBM, but only three of them,
PC (40:6) + Na+ (p < 0.01), PC (36:4)
+ K+ (p < 0.05), and PC (36:1) + Na+ (p < 0.01), were also regulated in the
cortex of lesioned rats (Figures and 3 and Supporting Information Table S1). However, a decrease of PC
(36:1) + Na+ (p < 0.05) was found in
the cortex. Although the precise physiological relevance of PC (36:1)
+ Na+ still remains unclear, its presence in rat brain
and in myelinated regions in human brain has previously been described.[37−39] Perhaps an incomplete removal of the BFCN debris and/or conversely
a partial remodeling process in an attempt to promote axonal sprouting
may explain the increase of this particular species in the NBM and
the decrease in the cortex.
Figure 2
Matrix-assisted laser desorption ionization
imaging mass spectrometry
(MALDI-IMS) of different lipids in brain slices containing the NBM
and cortical projections from aCSF (n = 8) and SAP-treated
rats (n = 8) which show marked differences in the
distribution of certain lipid species following the cholinergic lesion.
The intensities were measured in the areas marked with black squares
of the somatosensory cortex and the NBM. Scale bar = 5 mm.
Figure 3
Relative abundance of different lipid species in NBM (A) and cortex
(B), expressed as percentages of the control group values (aCSF):
*p < 0.05, **p < 0.01, and
***p < 0.001, SAP vs aCSF-treated rats.
Matrix-assisted laser desorption ionization
imaging mass spectrometry
(MALDI-IMS) of different lipids in brain slices containing the NBM
and cortical projections from aCSF (n = 8) and SAP-treated
rats (n = 8) which show marked differences in the
distribution of certain lipid species following the cholinergic lesion.
The intensities were measured in the areas marked with black squares
of the somatosensory cortex and the NBM. Scale bar = 5 mm.Relative abundance of different lipid species in NBM (A) and cortex
(B), expressed as percentages of the control group values (aCSF):
*p < 0.05, **p < 0.01, and
***p < 0.001, SAP vs aCSF-treated rats.On the other hand, some lipid species were clearly
up-regulated
after the lesion at both the NBM and cortex. PC (36:4) + K+, PC (38:4) + K+, and PC (40:6) + Na+, which
are mainly present in gray matter,[30] were
increased in both areas. The most probable composition of PC (40:6)
+ Na+ in brain is stearic acid (18:0) and docosahexaenoic
acid (DHA; 22:6), and of PC (36:4) + K+, palmitic acid
(16:0) and arachidonic acid (AA; 20:4). AA and DHA are classical polyunsaturated
fatty acids (PUFAs), which have been described to restore rat cerebral
Ch and ACh levels, improving their behavioral outcomes in the PA test.[40,41] The conversion of Ch to PC requires, among others, the combination
with PUFAs such as DHA.[42] In this regard,
the density of PC (40:6) and other Ch-containing phospholipids has
been found to be either increased[24,26] or decreased[23,25] in plasma samples from AD patients. The regulation of these specific
lipid species has been proposed as a biomarker of phenoconversion
to AD. The present results suggest that the general increase in these
three different PCs, induced after the cholinergic lesion of BFCN,
could represent a first response to the immunotoxin-induced massive
death of BFCN in the NBM, since neuroinflammatory processes could
still be present 7 days after lesioning, as indicated by the observed
general increase in Iba-1 immunostaining (microglial-specific marker).
The microglial proliferation showed a general increase in most of
the brain areas following the immunotoxin administration. Moreover,
the labeling was very high along the tract of the injection, especially
in the cortex and NBM (Figure ).
Figure 4
Hoechst staining (blue) and Iba1 (red), showing coronal representative
sections of rat brains in the proximity of the injection site: (A,
B, C, D, E) aCSF; (A′, B′, C′, D′, E′)
SAP-treated. The inset squares indicate the brain areas where the
microglia density is shown: (B, B′) cortical area near the
injection; (C, C′) correspondence to the injection site at
the NBM nucleus; (D, D′) cingulate cortex; (E, E′) area
of thalamic nuclei. Note the higher density of Iba-1 positive cells
(microglia) in lesioned animal, which is more noticeable and extended
at the lesion site in the NBM. Bar in (A) is 500 μm. Bar in
(B) is 100 μm.
Hoechst staining (blue) and Iba1 (red), showing coronal representative
sections of rat brains in the proximity of the injection site: (A,
B, C, D, E) aCSF; (A′, B′, C′, D′, E′)
SAP-treated. The inset squares indicate the brain areas where the
microglia density is shown: (B, B′) cortical area near the
injection; (C, C′) correspondence to the injection site at
the NBM nucleus; (D, D′) cingulate cortex; (E, E′) area
of thalamic nuclei. Note the higher density of Iba-1 positive cells
(microglia) in lesioned animal, which is more noticeable and extended
at the lesion site in the NBM. Bar in (A) is 500 μm. Bar in
(B) is 100 μm.Other non-PC lipids were
also found to be modified in the NBM,
such as reduced levels of phosphatidylethanolamines (PEs) (14:1/20:4)
+ H+ and sphingomyelins (SMs) (d18:1/18:0) + H+ (p < 0.05) and the increase of SM (d18:1/16:0)
+ K+ (p < 0.01). Interestingly, the
decreased levels of PE (14:1/20:4) in the NBM could reveal a process
of autophagy[43] or conversely be indicating
a possible source for de novo synthesis of Ch.[44] PEs from any membrane pool are sequentially
methylated to PC by phosphatidylethanolamine N-methyltransferase
and hydrolyzed to free Ch, a process that can be blocked by the mAChR
antagonist atropine.[12,45−47] Moreover, the
stimulation of cortical synaptosomes with cholinergic agonists (e.g.,
ACh, muscarine or carbachol) is able to increase phospholipase D (PLD)
activity, which is reduced by up to 63% in samples from AD patients.[48] Then, mAChR-mediated signaling may be involved
in the observed regulation of phospholipids after the BFCN lesion,
pointing to PE (14:1/20:4) as another possible precursor for de novo synthesis of Ch. Furthermore, the negative ion detection
mode revealed modifications in the levels of several additional lipid
species in the NBM, such as an increase of SM (d18:1/15:0) (p < 0.01) and PE (40:4) (p < 0.05)
and a reduction of phosphatidylserines (PS) (18:0/18:1) (aCSF 11.04
± 2.16% vs SAP 3.95 ± 0.99%, p < 0.01).
However, the level of only one species of phosphoglycerol (PG), PG
(22:6/22:6), was increased in the group of SAP-treated rats in NBM
and cortex (p < 0.05) (Figures and 3, Supporting Information Table S1). Under normal
physiological conditions, PS (18:0/18:1) is preferentially located
in the inner leaflet of the plasma membrane. The reduction of this
species and the loss of asymmetry, also described in AD patients,
could represent an early indicator of apoptosis and/or glia-mediated
synaptic pruning to remodel the damaged basal forebrain neural circuit.[49−51]The changes in SM are discussed below. On the one hand, a
significant
increase in the relative intensity of two species, SM (d18:1/15:0)
and SM (d18:1/16:0) + K+, was found in the NBM. On the
other hand, reduced levels of SM (d18:1/18:0) + H+ revealed
the loss of this particular species following the cholinergic lesion.
Sphingolipid metabolism is essential for tissue homeostasis, and the
catabolism of sphingolipids contributes to AD pathology.[52,53] Interestingly, SM is characterized by carrying a Ch in their molecular
structure and it is tempting to hypothesize that following the BFCN
lesion, SM could be exploited to maintain cortical cholinergic neurotransmission
when approximately 80% of the cortical cholinergic input has disappeared.
Since Ch is not stored in vesicles, the generation of pools of lipids
containing Ch for the further synthesis of ACh is difficult to understand,
and one would expect to observe a reduction in any possible SM species
for Ch synthesis, pointing to SM (d18:1/18:0) + H+ as a
plausible candidate. However, the increase in the relative density
of a specific SM species such as (d18:1/16:0) + K+ additionally
allows us to hypothesize that a possible reservoir is created by an
unknown storing mechanism from which to further obtain Ch. In AD patients,
a depletion of SM (d18:1/16:0) in brain-derived nanoparticles fraction
of CSF and a reduction in acid sphingomyelinase activity have been
reported,[54] whereas a marked increase in
SM (d18:1/18:0) has been found in the hippocampal gray matter and
in the CSF.[55,56] Nevertheless, as the IMS technique
allowed us to anatomically localize the specific up-regulation of
these three lipids along the tract of the needle used for the lesion,
we observed that it was coincident with the microglial response and
we do not rule out the possibility that this could additionally explain
the observed changes in distribution of these SM species.
Altered Functional
Coupling and Distribution of mAChR Following
Basal Forebrain Cholinergic Depletion
In an attempt to relate
the changes in the lipid distribution and cholinergic muscarinic signaling,
exhaustive autoradiographic and immunohistochemical studies were carried
out. To examine M2/M4 mAChR-mediated signaling,
the activity of Gi/o-coupled mAChR was rostrocaudally measured
from the medial septum to the ventral hippocampus by using [35S]GTPγS autoradiography assay (Figure , Supporting Information Tables S2–S4). The anatomical distribution and quantification
of M1 mAChR and M2 mAChR were performed using
[3H]-pirenzepine in the presence of unlabeled oxotremorine
and [3H]-oxotremorine in the presence of pirenzepine, respectively,
showing the characteristic patterns of distribution, i.e., M1 mAChR abundant in the cortical mantle, hippocampus, basal ganglia,
and amygdala, whereas M2 mAChRs are less abundantly distributed
in cortical and hippocampal regions and more in the basal forebrain
and in thalamic areas (Figure A,B, Supporting Information Table S5). To examine the cellular localization of mAChR, immunofluorescence
studies were performed using an antiserum against i3 intercellular
loop of human M1, M2, and M4 mAChR
(Figure ). The pattern
of distribution of M1, M2, and M4 mAChR was very similar to that observed in the autoradiographic
studies (Figure ).
Figure 5
[35S]GTPγS autoradiography in rat brain coronal
sections at two different levels from Bregma, (A) including NBM and
(B) including dorsal hippocampus, obtained from aCSF, left (n = 9), and SAP-treated rats, right (n =
11), that show representative autoradiograms of [35S]GTPγS
binding evoked by carbachol (100 μM). This assay is specific
to Gi/o coupled receptors; therefore we are measuring the
activity mediated by M2/M4 mAChR. The graphs
show the mean ± SEM of each group in the different analyzed areas.
NBM: nucleus basalis magnocellularis. D gyrus (granular): granular
dentate gyrus. CA3: CA3 region of hippocampus. S sensory: somatosensory
cortex. [14C]-Microscales were used as standards in nCi/g
t.e. Scale bar: 5 mm.
Figure 6
[3H]-Pirenzepine
binding (A) and [3H]-oxotremorine
binding (B) in rat brain coronal sections obtained from aCSF (n = 7) and SAP-treated rats (n = 9) that
show the specific distribution of M1 mAChR and M2 mAChR, respectively. Note the increase of both the M1 mAChR density in the hippocampus (A) and the M2 mAChR
density in the deepest layers of cortex (B) and in the anterior amygdala
of SAP-treated rats. Note also the loss of both M1 mAChR
in the anterior amygdala (A) and M2 mAChR in the NBM (B)
following the lesion. The histograms show the mean ± SEM of each
group in the different areas analyzed. Scale bar: 5 mm.
Figure 7
Double labeling in sections containing NBM from aCSF (A, C) and
192IgG-saporin-treated (B, D) rats, stained for ChAT (red) and M2 mAChR and M4 mAChR (green) at 200-fold magnification.
192IgG-saporin induced a reduction in BFCN density and in M2/M4 mAChR-immunoreactivity. Scale bars (B, D) = 40 μm.
High magnification images show M2 mAChR immunoreactivity
surrounding the perikarya (Aii) of the large BFCN (Ai) with a modest
degree of colocalization (Aiv), whereas M4 mAChR-immunolabeling,
surrounding the perikarya (Cii) of the large BFCN (Ci), shows a high
degree of colocalization (Civ). Interestingly, 192IgG-saporin-treated
rats show the presence of shrunk ChAT-immunoreactive neurons (Bi,
Di), where the loss of M2 and M4 mAChR immunoreactivity
is evident (Bii and Dii, respectively). Scale bars (Biv, Div) = 10
μm. Double labeling of consecutive sections containing hippocampal
CA3 pyramidal region (E, F) and somatosensory cortex (G, H) from one
SAP-treated rat, stained for ChAT (red), M2 mAChR (E and
G in green), and M4 mAChR (F and H in green) at 630-fold
magnification. The images show a presynaptic distribution of M2 mAChR, delineating the perikarya of the large CA3 pyramidal
neurons in basket-like formations (Eii) and the somatodendritic distribution
of M4 mAChR in the perikarya of the same neurons (Fii).
In the cortex, both M2 (G) and M4 (H) mAChR
distribution displays a similar pattern to that observed in CA3. Scale
bars (Fiv, Hiv) = 10 μm. M1 mAChR immunolabeling
in hippocampal CA3 region (I) and somatosensory cortex (J) from one
SAP-treated rat at 200-fold magnification. Scale bars (I, J) = 100
μm. 630-fold magnification images show M1 mAChR (Ki) immunoreactivity distributed surrounding
the nuclei (Kiii) in the perikarya of pyramidal neurons with a modest
degree of colocalization (Kiv) with the glutamatergic marker VGLUT3
(Kii). M2 mAChRs (Lii) are distributed in presynaptic GABAergic
terminals (Li) in basket-like formations surrounding the somatodendritic
compartment of pyramidal neurons of CA3 with a high degree of colocalization
(Liv). Scale bars = 10 μm.
[35S]GTPγS autoradiography in rat brain coronal
sections at two different levels from Bregma, (A) including NBM and
(B) including dorsal hippocampus, obtained from aCSF, left (n = 9), and SAP-treated rats, right (n =
11), that show representative autoradiograms of [35S]GTPγS
binding evoked by carbachol (100 μM). This assay is specific
to Gi/o coupled receptors; therefore we are measuring the
activity mediated by M2/M4 mAChR. The graphs
show the mean ± SEM of each group in the different analyzed areas.
NBM: nucleus basalis magnocellularis. D gyrus (granular): granular
dentate gyrus. CA3: CA3 region of hippocampus. S sensory: somatosensory
cortex. [14C]-Microscales were used as standards in nCi/g
t.e. Scale bar: 5 mm.[3H]-Pirenzepine
binding (A) and [3H]-oxotremorine
binding (B) in rat brain coronal sections obtained from aCSF (n = 7) and SAP-treated rats (n = 9) that
show the specific distribution of M1 mAChR and M2 mAChR, respectively. Note the increase of both the M1 mAChR density in the hippocampus (A) and the M2 mAChR
density in the deepest layers of cortex (B) and in the anterior amygdala
of SAP-treated rats. Note also the loss of both M1 mAChR
in the anterior amygdala (A) and M2 mAChR in the NBM (B)
following the lesion. The histograms show the mean ± SEM of each
group in the different areas analyzed. Scale bar: 5 mm.Double labeling in sections containing NBM from aCSF (A, C) and
192IgG-saporin-treated (B, D) rats, stained for ChAT (red) and M2 mAChR and M4 mAChR (green) at 200-fold magnification.
192IgG-saporin induced a reduction in BFCN density and in M2/M4 mAChR-immunoreactivity. Scale bars (B, D) = 40 μm.
High magnification images show M2 mAChR immunoreactivity
surrounding the perikarya (Aii) of the large BFCN (Ai) with a modest
degree of colocalization (Aiv), whereas M4 mAChR-immunolabeling,
surrounding the perikarya (Cii) of the large BFCN (Ci), shows a high
degree of colocalization (Civ). Interestingly, 192IgG-saporin-treated
rats show the presence of shrunk ChAT-immunoreactive neurons (Bi,
Di), where the loss of M2 and M4 mAChR immunoreactivity
is evident (Bii and Dii, respectively). Scale bars (Biv, Div) = 10
μm. Double labeling of consecutive sections containing hippocampal
CA3 pyramidal region (E, F) and somatosensory cortex (G, H) from one
SAP-treated rat, stained for ChAT (red), M2 mAChR (E and
G in green), and M4 mAChR (F and H in green) at 630-fold
magnification. The images show a presynaptic distribution of M2 mAChR, delineating the perikarya of the large CA3 pyramidal
neurons in basket-like formations (Eii) and the somatodendritic distribution
of M4 mAChR in the perikarya of the same neurons (Fii).
In the cortex, both M2 (G) and M4 (H) mAChR
distribution displays a similar pattern to that observed in CA3. Scale
bars (Fiv, Hiv) = 10 μm. M1 mAChR immunolabeling
in hippocampal CA3 region (I) and somatosensory cortex (J) from one
SAP-treated rat at 200-fold magnification. Scale bars (I, J) = 100
μm. 630-fold magnification images show M1 mAChR (Ki) immunoreactivity distributed surrounding
the nuclei (Kiii) in the perikarya of pyramidal neurons with a modest
degree of colocalization (Kiv) with the glutamatergic marker VGLUT3
(Kii). M2 mAChRs (Lii) are distributed in presynaptic GABAergic
terminals (Li) in basket-like formations surrounding the somatodendritic
compartment of pyramidal neurons of CA3 with a high degree of colocalization
(Liv). Scale bars = 10 μm.Following the lesion, the functionality of mAChR was found to be
decreased in the NBM (p < 0.05), unaltered in
cortical areas, and enhanced in the hippocampal pyramidal layer of
the CA3 (p < 0.05) and in the granular layer of
the dentate gyrus (p < 0.05) (Figure ). In the cortex, despite the
elimination of up to 70% of BFCN in some cortical regions (as measured
in the AChE assay, Figure G), no differences in the functional coupling of M2/M4 mAChR to Gi/o proteins were observed. The
mAChR autoradiographic studies revealed a loss of M2 mAChR
in the NBM (p < 0.001), whereas increased levels
were found in the superficial gray layer of superior colliculus (p < 0.05) as well as in several cortical regions (p < 0.05) (Figure B, Supporting Information Table S5). On the other hand, increased levels of M1 mAChR were
found in the oriens layer of hippocampal CA3 and in the granular region
of dentate gyrus (p < 0.01) but decreased levels
in the anterior amygdala (p < 0.05) (Figure A, Supporting Information Table S5). BFCN of NBM displayed a
modest somatodendritic immunostaining, but the presence of a dense
network of fibers surrounding the somas revealed presynaptic contacts
from M2 mAChR-positive axon terminals (Figure Eiv).SAP-treated rats
showed an almost total absence of M2 mAChR-immunoreactivity
in the basal forebrain due to the near disappearance
of BFCN, as revealed by ChAT immunostaining (Figure Biv). On the other hand, M4 mAChR-immunoreactivity
was distributed mainly in somatodendritic compartments in NBM (Figure C,D), hippocampus
and cortex (Figure Fii,Hii), displaying a typically postsynaptic localization. Immunotoxin-treated
rats showed a dramatic decrease in M4 mAChR-immunoreactivity
in the basal forebrain, accompanied by the disappearance of BFCN (Figure Dii). These findings
demonstrate the contribution of these receptors to the cholinergic
neurotransmission impairment and the loss of cholinergic interconnections
in the basal forebrain. Although the precise anatomical distribution
of M2 and M4 mAChR in the NBM remains controversial,
the present immunohistochemical findings suggest a mainly presynaptic
localization of M2 mAChR and a somatodendritic distribution
of M4 mAChR. This specific localization is important to
understand the physiological consequences of the lesion. In the somatosensory
cortex, M2 mAChR presented a scattered distribution in
presumably presynaptic compartments (Figure Gii). A high expression of postsynaptic M1 mAChR was found in the cortical mantle, the hippocampus,
the amygdaloid complex, and striatum (Figure I,J). At the subcellular level, the mAChR
subtypes were differentially distributed in the CA3 region of the
hippocampus. M1 mAChR (Figure Kiv) and M4 mAChR (not shown)
were distributed in glutamatergic postsynaptic compartments, while
a high degree of colocalization between M2 mAChR and the
presynaptic GABAergic marker GAD65 was observed (Figure Liv). M2 mAChR-immunoreactivity
was differentially distributed throughout the hippocampal formation.
The large pyramidal neurons from CA1–CA3 and dentate gyrus
displayed a dense network of fibers, which delineate the perikarya
in basket-like formations, without immunoreactivity in the soma (Figure Eiv,Lii). In the
granular dentate gyrus and pyramidal CA1–CA3, M2 mAChRs are located in inhibitory GABAergic presynaptic terminals,
whereas M1 and M4 mAChRs are distributed in
the somatodendritic compartment of pyramidal neurons. The increase
in cortical M2 mAChR may indicate a secondary regulation
of cortical M2 mAChR, which is consistent with previous
studies.[16,57−61] Regarding the modulation of hippocampal cholinergic
signaling, lesions directed at the medial septum-vertical diagonal
band complex have demonstrated a decrease in both density and activity
of mAChR, revealing completely opposite effects to those observed
when the NBM is lesioned.[62−66] The absence of nonspecific damage to the SM-vertical diagonal band
complex indicates that the increase in M2/M4 mAChR-mediated signaling in the hippocampus should also be considered
as a secondary modulation of muscarinic signaling. In the hippocampus,
M2 mAChR inhibits ACh release, while M1 mAChR
potentiates glutamatergic signaling.[65,67−69] Moreover, mice lacking M2 mAChR showed deficits in learning
during avoidance and spatial memory tests, demonstrating the role
of this receptor subtype in cognitive processes which are dependent
on both short- and long-term potentiation and completely reversed
with GABAA receptor antagonists.[70,71] Therefore, the immunotoxin-induced increase in hippocampal muscarinic
functionality mediated by M2 mAChR could be decreasing
the GABAergic tone and increasing glutamatergic transmission as a
compensatory mechanism following the lesion of the NBM, contributing
to the so-called “muscarinic long-term potentiation”,
which is essential to explain hippocampal neuronal plasticity.[72]
Muscarinic Receptor-Mediated Signaling Induces
Specific Changes
in the Lipid Profile in ex Vivo Organotypic Cultures
The MALDI-IMS technique was also used to semiquantify the relative
intensity of several lipids after specific mAChR stimulation in ex vivo organotypic cultures. The immunofluorescence studies
carried out in the basal forebrain cholinergic system from P7 rats
revealed the presence of a high density of BFCN expressing p75NTR
supporting the rationale of using this model to further investigate
the modulation of lipid composition mediated by muscarinic signaling
(Figure ). Ex vivo organotypic cultures including the BFCN and cortical
regions were used to analyze the lipid modifications following treatment
with the muscarinic agonist carbachol or with the nonselective antagonist
scopolamine and the M1 selective pirenzepine.
Figure 8
Low magnification
(2.5×) photomicrographs of Hoechst staining
in 10 μm tissue slices from P7 rats including the medial septum
(MS) (1A), both vertical diagonal band of Broca (1B) and horizontal
diagonal band of Broca (1C) and the NBM (2D) (scale bar = 1 mm). P75NTR immunofluorescence in the MS (A, A1). Vertical
diagonal band (B, B1). Horizontal diagonal band (C, C1). NBM (D, D1). (C, D) Scale bar = 100 μm.
(C1, D1) Scale bar = 50 μm.
Low magnification
(2.5×) photomicrographs of Hoechst staining
in 10 μm tissue slices from P7 rats including the medial septum
(MS) (1A), both vertical diagonal band of Broca (1B) and horizontal
diagonal band of Broca (1C) and the NBM (2D) (scale bar = 1 mm). P75NTR immunofluorescence in the MS (A, A1). Vertical
diagonal band (B, B1). Horizontal diagonal band (C, C1). NBM (D, D1). (C, D) Scale bar = 100 μm.
(C1, D1) Scale bar = 50 μm.We found decreased levels of several PC induced by carbachol
(e.g.,
36:4, O-36:4, 36:5, 38:5, 38:6, 38:7, O-38:7, and 40:7+ H+) (Supporting Information Table S6). Different
pathways related to muscarinic signaling could govern the metabolism
of PC including the following: phospholipase C-mediated degradation
leading to formation of diacylglycerol (DAG) and phosphocholine or
phospholipase D catalyzing the hydrolysis to phosphatidic acid (PA)
and Ch.[73−76] However, we only found increased lysophosphatidylcholines (LPCs)
(16:0, 16:1, 18:0, 18:1, and 18:2) + H+ and LPC (O-18:0)
−CH3. LPC species are derived by the cleaving of
PC via the action of phospholipase A2 (PLA2) hydrolyzing the fatty
acid at position 2 of phospholipids, generating free fatty acid (DHA
or AA).[77,78] More studies are needed to completely discard
the action of phospholipase C or PLD activation, since the absence
of an increase of DAG and PA levels in organotypic cultures could
be a result of the downstream degradation in their signaling pathways.
Conversely, the negative correlation between the reduction of PC and
the increase of LPC supports the PLA2 action by mAChR activation (Figure ). In addition, the
modulation of PC and LPC species after carbachol administration is
abolished by scopolamine but not with pirenzepine, suggesting that
this effect is not dependent on M1 mAChR. In this sense,
several studies support the involvement of PLA2 in the production
of free Ch for the synthesis of ACh, which is found coupled to mAChR.[79,80] As previously shown, decreased muscarinic activity in NBM after
the lesion could be related to the increase of PC in NBM by a PLA2
down-regulation. Finally, common lipid species (PC 36:4, 38:7, and
38:4 + H+) were found to be increased in vivo following cholinergic depletion and decreased in ex vivo organotypic cultures after mAChR activation. All the results indicate
that these PC species could be possible lipid precursors of ACh in
this specific pathway.
Figure 9
Correlation analyses between PC 36:4, PC 38:6, and PC
38:5 with
LPC 16:0 and 18:0 in organotypic cultures following three different
experimental treatments (vehicle, carbachol 1 μM, and carbachol
1 μM + scopolamine 1 μM): *p < 0.05,
**p < 0.01, and ***p < 0.001.
Correlation analyses between PC 36:4, PC 38:6, and PC
38:5 with
LPC 16:0 and 18:0 in organotypic cultures following three different
experimental treatments (vehicle, carbachol 1 μM, and carbachol
1 μM + scopolamine 1 μM): *p < 0.05,
**p < 0.01, and ***p < 0.001.The dramatic reduction of AChE staining in basal
forebrain and
projections to cortical areas, together with the observed learning
and memory impairment, validates the use of this model of NBM lesion
in rat for the study of possible adaptations of the lipid profile
in relation to cholinergic neurotransmission impairment. The loss
of most of the BFCN shortened the ACh supply, but part of these cells,
which continue to be physiologically active, could make use of specific
membrane PL precursors of Ch as an emergency source for obtaining
the cholinergic neurotransmitter. The reduction in phospholipid levels
could lead to a decrease of membrane reservoirs available for different
purposes including dendritic spinogenesis for new synapses after long-term
potentiation processes (learning). In fact, we observed shrinkage
of the surviving BFCN. The hydrolysis of PL from membranes of presynaptic
terminals (cortical area) and/or somatodendritic compartment (NBM
area) may be responsible for the selective regulation of certain lipid
species following the lesion that could be controlled by muscarinic
signaling. MALDI-IMS analysis showed changes in the lipid profile,
which include some specific species of PC, PE, PS, and SM. Despite
the abundance of M1 mAChR in cortical regions, both autoradiographic
and immunohistochemical results failed to show changes induced by
the cholinergic lesion, which suggests that M1 mAChR-mediated
signaling may not be related to the observed lipid modulation. Thus,
the observed modulation of the lipidome by the cholinergic metabolism
is probably mediated mainly by those mAChR coupled to Gi/o proteins (i.e., M2 and M4 subtypes). Possible
choline precursors such as some PC species, are increased in the rat
lesion model at the NBM, where the M2 mAChR density and
activity are decreased, diminishing the PLA2 activity that results
in higher PC levels. Conversely, the M2/4 mAChRs are up-regulated
in the cortex of lesioned rats and consequently the PC intensities.Altogether the above-described processes indicate the control of
PC metabolism by M2/4 mAChR when the availability of ACh
is compromised.
Conclusions
In summary, the loss
of cortical cholinergic innervation leads
to learning and memory impairment involving the modulation of the
activity of M2/M4 mAChR in the NBM and hippocampus
but not in the cortex, despite the fact that increased densities of
M2 mAChR were recorded in several cortical regions. Moreover,
an up-regulation of M1 mAChR was observed in the hippocampus
together with changes in M2/M4 mAChR activity
in this specific brain region, revealing a secondary modulation of
muscarinic signaling. The present findings show up-regulated lipid
levels indicating not only a first microglial response but also the
specific cortical down-regulation of potential Ch precursors as an
alternative source for ACh. This regulation may not be mediated through
M1 mAChR. However, we cannot rule out the possibility of
a Gi/o-coupled mAChR-mediated (i.e., M2 mAChR)
modulation of the lipid composition. The present results contribute
to the understanding of the brain adaptations involving microglial
response, possible de novo synthesis of Ch and the
mAChR-mediated regulation of lipid metabolic pathways following the
specific loss of BFCN and cholinergic input. The AD rat model used
in the present study provides us with a suitable tool with which to
obtain further knowledge about the relationship between ACh metabolism
and muscarinic signaling. Future treatments for AD based on potentiating
cholinergic neurotransmission could involve the regulation of the
lipid metabolism through modulation of specific mAChR subtypes.
Methods
Chemicals
192IgG-saporin
(batch 2441969) was acquired
from Millipore (Temecula, CA, USA). RRID AB_94979, [3H]-pirenzepine
(86.0 Ci/mmol, catalog no. NET80250UC), [3H]-oxotremorine
(75.8 Ci/mmol, catalog no. NET671), and [35S]GTPγS
(1250 Ci/mmol, catalog no. NEG030H250UC) were from PerkinElmer (Boston,
MA, USA). Both [3H]- and [14C]-microscales (catalog
no. ART0123A and catalog no. ARC0146, respectively) were used as standards
in the autoradiographic experiments, ARC (American Radiolabeled Chemicals,
Saint Louis, MO, USA). The β-radiation-sensitive Kodak Biomax
MR films (catalog no. 7358460), bovine serum albumin (BSA) (catalog
no. A4503), carbachol (catalog no. C4382), pirenzepine (catalog no.
P7412), oxotremorine (catalog no. O9126), atropine (catalog no. A0257)
scopolamine (catalog no. S0929), dl-dithiothreitol (DTT)
(catalog no. D5545), adenosine deaminase (ADA) (catalog no. A9876),
guanosine 5′-diphosphate (GDP) (catalog no. G7127), guanosine
5′-O-3-thiotriphosphate (GTPγS) (catalog
no. G8634), ketamine (catalog no. K2753), xylazine (catalog no. X1251),
acetylthiocholine iodide (catalog no. 01480), 2-mercaptobenzothiazole
(MBT) (catalog no. M3302), and tetraisopropyl pyrophosphoramide (iso-OMPA)
(catalog no. T1505) were all acquired from Sigma-Aldrich (St. Louis,
MO, USA).
Animals
Ninety-seven adult male Sprague-Dawley rats,
weighing 225–275 g and ranging in age from 8 to 10 weeks, were
used in this study. Rats were housed four per cage (50 cm, length
× 25 cm, width × 15 cm, height) at a temperature of 22 °C
in a humidity-controlled (65%) room with a 12:12 h light/dark cycle
with access to food and water ad libitum. Seven rat pups at postnatal
day 7 (P7) weighed 14–20 g at the start of the ex vivo experiments based on hemibrain organotypic cultures containing BFCN.All procedures were performed in accordance with European animal
research laws (Directive 2010/63/EU) and the Spanish National Guidelines
for Animal Experimentation (RD 53/2013, Law 32/2007). Experimental
protocols were approved by the Local Ethics Committee for Animal Research
of the University of the Basque Country (CEEA 388/2014). The authors
further attest that all efforts were made to minimize the number of
animals used and their suffering.
Ex Vivo Organotypic Cultures
To prepare
hemibrain organotypic cultures, P7 Sprague-Dawley rats (n = 7) were sacrificed by decapitation and their brains were quickly
dissected under aseptic conditions inside a laminar flow cabinet (TELSTAR,
BV-30/70).[81] After removal of the olfactory
bulb and the most caudal part of the cerebellum, the brains were placed
in minimal essential Dulbecco′s modified Eagle medium (DMEM,
Sigma-Aldrich) supplemented with 0.1% (v/v) antibiotic/antimycotic
(Gibco) at 4 °C.The brains were vertically positioned
resting on the cerebellum by means of cyanoacrylate. They were then
cut, from the rostral to the caudal part, into coronal 300 μm
thick organotypic slices using a sliding vibratome (Leica VT 1.000
S, Leica Microsystems AG, Wetzlar, Germany). Approximately 6 slices
containing the medial septum and another 6 slices containing the NBM
were obtained from each brain, and these were immediately transferred
into cell culture inserts over membranes of 0.4 μm pore size
(PIC50ORG, Millipore, MA, USA). The organotypic slices were then placed
in 6-well cell culture plate (Falcon, BD Biosciences Discovery Labware,
Bedford, MA) that contained 1 mL of culture medium per well. The culture
medium consisted of 49% (v/v) neurobasal medium (NB, Sigma-Aldrich),
24% (v/v) Hanks’ balanced salt solution (HBSS, Gibco), 24%
(v/v) normal horse serum (NHS, Gibco), 1% (v/v) d-glucose,
0.5% glutamine (Sigma-Aldrich), 0.5% B27 supplement serum free (Gibco),
and 1% antibiotic/antimycotic. The culture plates were incubated at
37 °C in a fully humidified atmosphere supplemented with 5% CO2, and the cell culture medium was replaced by fresh medium
on the second day.
Basal Forebrain Cholinergic Lesion
All surgery was
carried out under aseptic conditions. 192IgG-saporin was used to selectively
eliminate BFCN in the NBM. Rats were randomly assigned to one of three
groups: sham-operated (SHAM; n = 6), artificial cerebrospinal
fluid, used as vehicle (aCSF; n = 44), and 192IgG-saporin
(SAP; n = 47). SHAM was the first group analyzed.
Then, aCSF- and SAP-treated animals were further assessed in five
independent groups (aCSF, n = 9; SAP, n = 9). The vehicle was prepared as follows: 0.15 M NaCl, 2.7 mM KCl,
0.85 mM MgCl2, 1.2 mM CaCl2 (pH 7.4) and sterilized
by filtration with 0.4 μm ⌀ filters (EMD Millipore, CA,
USA). The intraparenchymal infusion of aCSF or SAP was made into the
NBM: −1.5 mm anteroposterior from Bregma, ±3 mm mediolateral
from midline, +8 mm dorsoventral from cranial surface,[82] as previously described.[17] Rats were kept warm and hydrated and continuously monitored
during surgery. Following surgery, they were kept away from other
animals until fully recovered.
Passive Avoidance Test
The rats were allowed seven
complete days to recover from surgery and were then subjected to the
passive avoidance test (PanLab passive avoidance box LE870/872). The
passive avoidance test involves two sessions. The first, which is
called “the learning trial”, was performed on day 7
after surgery beginning at 8 a.m. Each animal (SHAM, n = 6; aCSF, n = 36; SAP, n = 36)
was gently placed in the illuminated compartment and allowed to explore
it for 30 s. Then, the guillotine door was automatically opened and
the rat was given a maximum of 60 s to enter the dark compartment.
When the rat crossed the doorway the door closed, the acquisition
latency time (i.e., the time that the rats remained in the open-topped
compartment) was measured, and a foot shock (0.4 mA/2 s) was delivered.
10 s after the foot shock, the rat was returned to its home cage.
24 h later beginning at 8 a.m., for the second session called “the
retention trial”, the rats were again placed in the illuminated
compartment and allowed to explore for 30 s. Then the door opened
and the step-through latency time (i.e., time taken to enter the dark
compartment), was measured, with a cutoff of 300 s. Another group
of rats (n = 19; aCSF, n = 8; SAP, n = 11) was used to record the electric-shock-evoked first
vocalization by two observers when delivering increasing foot shock
intensities. Each animal was gently placed in the illuminated compartment
and allowed to explore it for 30 s. When the rat crossed the doorway,
increasing intensities of 0.05 mA lapses (1 s duration) and ranging
from 0.0 mA to 0.4 mA were given, and the minimum electrical intensity
for the first audible vocalization was recorded. These animals were
discarded from further behavioral studies.
Tissue Preparation
Following the passive avoidance
test, all the animals were anesthetized with ketamine/xylazine (90/10
mg/kg; ip) and killed by decapitation or transcardially perfused to
obtain fresh or fixed tissue, respectively.
Fresh Tissue
The
brains from aCSF (n = 31) and SAP (n = 32) groups were quickly removed
by dissection, fresh frozen, and kept at −80 °C. Later,
they were cut into 20 μm sections using a Microm HM550 cryostat
(Thermo Scientific) equipped with a freezing-sliding microtome at
−25 °C and mounted onto gelatin-coated slides and stored
at −25 °C until used.
Fixed Tissue
Representative
animals from aCSF and SAP
groups, which showed a positive or negative response respectively
in the passive avoidance test, were transcardially perfused with 50
mL of warm (37 °C), calcium-free Tyrode’s solution (0.15
M NaCl, 5 mM KCl, 1.5 mM MgCl2, 1 mM MgSO4,
1.5 mM NaH2PO4, 5.5 mM glucose, 25 mM NaHCO3; pH 7.4), 0.5% heparinized, followed by 4% paraformaldehyde
and 3% picric acid in 0.1 M phosphate buffer (PB) (4 °C) (100
mL/100 g, bw) (37 °C, pH 7.4). The brains were removed, followed
by immersion in a cryoprotective solution of 20% sucrose in PB overnight
at 4 °C, and then frozen by immersion in isopentane and kept
at −80 °C. Later they were coronally cut into 10 μm
sections as described above and mounted onto gelatin-coated slides
and finally stored at −25 °C until use for the immunofluorescence
assays.After 2 days in vitro, organotypic
cultures were treated with vehicle (0.9% saline solution), carbachol
(1 μM), carbachol (1 μM) and scopolamine (1 μM)
or carbachol (1 μM) and pirenzepine (1 μM) for 72 h, respectively.
Then, organotypic culture tissue from vehicle (n =
3), carbachol (n = 2), carbachol and scopolamine
(n = 2) or carbachol and pirenzepine (n = 2) conditions were washed with 0.1 M PB. Lastly, samples were
homogenized using a Potter-Elvehjem tissue homogenizer in water and
centrifuged at 15 000 rpm for 15 min at 4 °C. The pellet
was frozen at −80 °C until IMS experiment was carried
out.Other organotypic cultures with no treatment (n = 2) were used for immunohistochemical studies. They were rinsed
with 0.9% saline solution (37 °C) followed by immersion in 4%
paraformaldehyde and 3% picric acid in 0.1 M PB (4 °C) for 1
h. Then, the fixed organotypic slices were extensively rinsed in 0.1
M PB (pH 7.4).
AChE Staining and Quantitative Analysis
Fresh tissue
slices containing basal forebrain and hippocampus from aCSF (n = 13) and SAP (n = 13) treated rats were
fixed in 4% paraformaldehyde in PB (0.1M) for 30 min at 4 °C
and washed in 0.1 M PBS, pH 7.4, for 20 min. Cholinergic innervations
were stained using the “direct coloring” thiocholine
method for AChE[83] as follows. The sections
were rinsed twice in 0.1 M Tris-maleate buffer (pH 6.0) for 10 min
and incubated for 100 min in complete darkness in the AChE reaction
buffer (0.1 M Tris-maleate, 5 mM sodium citrate, 3 mM CuSO4, 0.1 mM iso-OMPA, 0.5 mM K3Fe(CN)6, and 2
mM acetylthiocholine iodide). The enzymatic reaction was stopped with
two consecutive rinses (2 × 10 min) in 0.1 M Tris-maleate (pH
6.0). The sections were scanned at 600 ppi, and the images were converted
to 8-bit gray scale mode. AChE positive fiber density was quantified
using ImageJ software (NIH, Bethesda, MD, USA). The intensity values
in arbitrary units were defined in the selected equivalent areas from
both hemispheres. Background was subtracted from AChE positive signals
to obtain the net AChE optical density in each area. AChE staining
values in the striatum served as control, and data were expressed
for each brain area as a percentage of striatal levels.
[35S]GTPγS Autoradiography and Quantitative
Analysis of Autoradiograms
The functional coupling of mAChR
to Gi/o proteins was measured in fresh frozen 20 μm
sections from each rat of both groups, aCSF (n =
9) and SAP (n = 11), as previously described.[33] The slides were exposed to β-radiation-sensitive
autoradiographic films in hermetically closed cassettes together with
a set of [14C] standards to calibrate the images (gray
densities). The films were developed after 48 h, scanned, and quantified
by transforming optical densities into nCi/g tissue equivalent (nCi/g
t.e.) using a calibration curve defined by the known values of the
[14C] standards using ImageJ software (RRID SCR_003070).
The specific binding for each area was calculated using consecutive
sections as follows. Nonspecific binding values were subtracted from
the values obtained in both agonist-stimulated and basal-stimulated
conditions. Then, the net basal stimulation values were subtracted
from agonist-stimulated values to obtain net agonist-stimulation ([agonist-stimulated
– nonspecific] – [basal – nonspecific]). The
percentages of carbachol-evoked stimulation were calculated according
to the following formula: ([35S]GTPγS agonist-stimulated
binding × 100/[35S]GTPγS basal binding) –
100.
Autoradiographic Labeling and Quantification of M1 mAChR and M2 mAChR by Using [3H]-Pirenzepine
and [3H]-Oxotremorine
Fresh 20 μm brain
sections from aCSF (n = 7) and SAP (n = 9) groups were dried for 10 min and submerged at room temperature
(RT) for 15 min in Krebs buffer (11 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 1.18 mM MgSO4·7H2O, 25 mM NaHCO3, 5.5 mM glucose, 1.18 mM KH2PO4; pH
7.4) for M1 mAChR or in 20 mM HEPES buffer for M2 mAChR. Then, the incubation was performed at RT for 1 h in Krebs
buffer in the presence of [3H]-pirenzepine (3 nM) and nonlabeled
oxotremorine (300 nM) for labeling M1 mAChR or for 40 min
in HEPES supplemented with [3H]-oxotremorine (2 nM) and
nonlabeled pirenzepine (100 nM) for labeling M2 mAChR.
In both cases, the nonspecific binding was measured by competition
with nonlabeled atropine (10 μM) in another consecutive slice.
Then, sections were washed in ice-cold (4 °C) 50 mM Tris-HCl
buffer (pH 7.4) to stop the binding, dipped in distilled ice-cold
water, and dried (4 °C). Autoradiograms were generated by exposure
of the tissues for 35 days ([3H]-oxotremorine) or 52 days
([3H]-pirenzepine) at 4 °C to β-radiation-sensitive
films in hermetically closed cassettes together with [3H]-microscales, which were used to calibrate the optical densities
to fmol/mg tissue equivalent (fmol/mg).
Immunofluorescence Studies
In order to perform the
immunofluorescence assays, the frozen fixed tissue sections were previously
dried at RT for 20 min. Anatomical distribution of BFCN was studied
using goat anti-choline acetyltransferase (ChAT) [1:200] (RRID AB_2079751)
as primary antiserum. To study the cellular localization of mAChR,
primary rabbit anti-M1 mAChR [1:400] (RRID AB_2260554),
rabbit anti-M2 mAChR [1:400] (RRID AB_2080068), mouse anti-M4 mAChR [1:250] (RRID AB_2080217), guinea pig antivesicular
glutamate transporter 3 (VGLUT 3) [1:500] (RRID AB_2187832), and mouse
antiglutamic acid decarboxylase isoform 65 kDa (GAD65) [1:750] (RRID
AB_2263126) (EMD Millipore, CA, USA) were used. To detect microglial
cells, primary rabbit polyclonal anti Iba-1 [1:1000] (Fujifilm Wako
Chemicals, USA) was used. Primary antibodies were diluted in PBS (0.1
M, pH 7.4) containing 0.5% BSA, and the tissue samples were incubated
overnight at 4 °C. They were then washed for 30 min in PBS and
incubated for 30 min at 37 °C with the appropriate secondary
antibodies. ChAT immunostaining was revealed with rhodamine-labeled
donkey anti-goat [1:80] (RRID AB_2340388). M1 and M2 mAChR and Iba-1 were revealed with Alexa-fluor 488-labeled
donkey anti-rabbit [1:250] (RRID AB_2535792) or CY3-labeled donkey
anti-rabbit [1:250] (RRID AB_2307443). M4 mAChR and GAD65
were revealed with Alexa-fluor 488-labeled donkey anti-mouse [1:250]
(RRID AB_141607), and VGLUT3 was revealed with Alexa-fluor 488-labeled
donkey anti-guinea pig [1:250] (RRID AB_2340472). Then, the sections
were incubated with Hoechst 33258 [1:106] (catalog no. B2883) for
15 min. Finally, sections were washed for 30 min by immersion in PBS
and mounted with p-phenylenediamine-glycerol (0.1%)
for immunofluorescence. 630-fold magnification images for colocalization
(M2 mAChR-ChAT, M4 mAChR-ChAT, M2 mAChR-GAD65, and M1 mAChR-VGLUT3) were acquired on an
Axioskop Observer A1 inverted microscope (Carl Zeiss) by optical sectioning
(0.24 μm/XYZ-resolution) using structured illumination
(ApoTome, Carl Zeiss). Colocalization images were created using ZEN2014
software (Carl Zeiss) and defined as immunosignals without physical
signal separation.Fixed organotypic slices were extensively
rinsed in 0.1 M PB (pH 7.4) and simultaneously blocked and permeabilized
with 4% normal goat serum (NGS) in 0.6% Triton X-100 in PBS (0.1 M,
pH 7.4) for 2 h at 4 °C. All incubations were performed in free
floating at 4 °C (48 h) with rabbit anti p75NTR primary antibody,
diluted in 0.6% Triton X-100 in PBS with 5% BSA. The primary antibody
was then revealed by incubation for 30 min at 37 °C with Alexa
488-labeled donkey anti-rabbit secondary antibody diluted in Triton
X-100 (0.6%) in PBS. Then, organotypic slices were washed for 30 min
by immersion in PBS and incubated for 15 min at room temperature with
Hoechst 33258 for fluorescent counterstaining of the nuclei. Finally,
slices were extensively rinsed with PBS and covered with p-phenylendiamine-glycerol (0.1%) in PBS for immunofluorescence observation.
Sample Preparation for MALDI-IMS
Lipid composition
and anatomical distribution were analyzed using MALDI-imaging mass
spectrometry (IMS) in fresh 20 μm sections from each rat from
the aCSF (n = 8) and SAP (n = 8)
groups, following the recommendations of ref (84). Once the tissue was sliced
and mounted on slides, MBT matrix was deposited on the tissue surface
by sublimation. The sublimation was performed using 300 mg of MBT,
and the deposition time and temperature were controlled (23 min, 100
°C). For the recrystallization of the matrix, the sample was
attached to the bottom of a glass Petri dish face-down, which was
placed on another Petri dish containing a methanol-impregnated piece
of filter paper in its base. The Petri dish were then placed on a
hot plate (1 min, 38 °C).Then, lipid composition was analyzed
in organotypic cultures. First, a dry pellet from organotypic cultures
was obtained and the protein concentration was determined using the
Bradford method.[85] Samples were reconstituted
with water at the same concentration. Then, a mixed sample (3 μL
of sample and 7 μL of matrix-saturated solution of MBT) was
deposited on MALDI plate containing 96 wells, using the dried droplet
method.
Mass Spectrometer and Image and Spectra Analysis
A
MALDI LTQ-XL-Orbitrap (Thermo Fisher, San Jose, CA) equipped with
a nitrogen laser (λ = 337 nm, rep rate = 60 Hz, spot size =
80 μm × 120 μm) was used for mass analysis. Thermo’s
Imagequest and Xcalibur software were used for MALDI-IMS data and
image acquisition in both positive and negative ion modes. The positive
ion range was 500–1000 Da, and the negative ion range was 400–1100
Da, with 10 laser shots per pixel at a laser fluence of 15 μJ.
The target plate stepping distance was set at 150 μm for both x- and y-axes by the MSI image acquisition
software. The data were normalized using the total ion current values,
as there may be potential displacement of the masses on the tissue
due to experimental factors, e.g., the irregularities of the surface.
The MALDI images were generated using ImageQuest (Thermo Scientific).
Each of the m/z values was plotted
for signal intensity for each pixel (mass spectrum) across a given
area (tissue section) using MSiReader software.[86] The m/z range of interest
was normalized using the ratio of the total ion current for each mass
spectrum. The intensity reached by each peak of the spectrum (m/z or molecule) was further calculated
as a ratio of the peak with the highest intensity, and the average
was obtained using OriginPro8 (Northampton, MA, USA) software. The
most intense peak (m/z or molecule)
was considered to be 100%. In the organotypic cultures the most intense
peak was modified after treatments; therefore the data were expressed
as absolute intensity in arbitrary units.The assignment of
lipid species was facilitated by the use of the databases Lipid MAPS
(http://www.lipidmaps.org/) and the Human Metabolome Database (HMDB) (https://hmdb.ca). 5 ppm mass accuracy was selected as the tolerance
window for the assignment.
Statistical Analyses
Step-through
latencies were represented
as Kaplan–Meier survival curves, and for comparisons between
groups, the log-rank/Mantel–Cox test was used. Kolmogorov–Smirnov
analyses were run to check the Gaussian distribution of the data obtained.
Acquisition latencies and absolute intensity of lipids were analyzed
by one-way analysis of variance (ANOVA) followed by Bonferroni′s
post hoc test for multiple comparisons and Spearman rank for correlations
(Sigma Plot 12.5, Systat Software, San Jose, CA). AChE densities,
the percentages of agonist-evoked [35S]GTPγS stimulation,
the density of M1 and M2 mAChR (fmol/mg t.e.),
the electric-shock-evoked first vocalization, and the percentages
of the relative intensity of lipids were statistically analyzed using
the two-tailed unpaired Student t test. The statistical
analyses were performed by using the GraphPad Prism 5.01 software.
The statistical significance threshold was set at p < 0.05.
Authors: E Gónzalez de San Román; I Manuel; M T Giralt; I Ferrer; R Rodríguez-Puertas Journal: Biochim Biophys Acta Biomembr Date: 2017-05-17 Impact factor: 3.747
Authors: Mark Mapstone; Amrita K Cheema; Massimo S Fiandaca; Xiaogang Zhong; Timothy R Mhyre; Linda H MacArthur; William J Hall; Susan G Fisher; Derick R Peterson; James M Haley; Michael D Nazar; Steven A Rich; Dan J Berlau; Carrie B Peltz; Ming T Tan; Claudia H Kawas; Howard J Federoff Journal: Nat Med Date: 2014-03-09 Impact factor: 53.440
Authors: Antonio Veloso; Egoitz Astigarraga; Gabriel Barreda-Gómez; Iván Manuel; Isidro Ferrer; María Teresa Giralt; Begoña Ochoa; Olatz Fresnedo; Rafael Rodríguez-Puertas; José A Fernández Journal: J Am Soc Mass Spectrom Date: 2011-01-28 Impact factor: 3.109
Authors: Alfred N Fonteh; Cora Ormseth; Jiarong Chiang; Matthew Cipolla; Xianghong Arakaki; Michael G Harrington Journal: PLoS One Date: 2015-05-04 Impact factor: 3.240
Authors: Alberto Llorente-Ovejero; Iker Bengoetxea de Tena; Jonatan Martínez-Gardeazabal; Marta Moreno-Rodríguez; Laura Lombardero; Iván Manuel; Rafael Rodríguez-Puertas Journal: ACS Pharmacol Transl Sci Date: 2022-08-04
Authors: Estibaliz González de San Román; Alberto Llorente-Ovejero; Jonatan Martínez-Gardeazabal; Marta Moreno-Rodríguez; Lydia Giménez-Llort; Iván Manuel; Rafael Rodríguez-Puertas Journal: Int J Mol Sci Date: 2021-11-12 Impact factor: 5.923